There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs that are highly effective,” Dr. Califf said. If doctors who read the ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase ... results of its next-generation weight loss drug CagriSema. After a late-stage trial slightly missed expectations, the ...

President Trump’s proposed tariffs on Denmark could have costly consequences for Americans relying on GLP-1 medications like Ozempic and Wegovy—and consumers are becoming increasingly concerned.

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs ... cases of a rare eye condition after concerns it could be linked to Ozempic.

Around 2.3 million Medicare patients used Novo drugs made with semaglutide - which includes Ozempic, Wegovy and Rybelsus ... Novo Nordisk were already down before the publication of the list ...